Harvard Bioscience Introduces Next Generation Inhalation System to Aid in the Fight Against COVID-19
Company will continue to manufacture and ship innovative products for global development and research throughout crisis
HOLLISTON, Mass., March 23, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) has launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) – for academic
researchers, contract research organizations (CROs) and pharmaceutical companies involved in pre-clinical inhalation and exposure studies. With our new Buxco AIA system, researchers are presented
with real-time aerosol amounts inhaled and deposited in subjects’ lungs, a breakthrough improvement over the current delivered dose measurement. By reporting those measures against real-time
respiratory endpoints using FinePointe software, researchers can now observe a direct correlation between dose and lung function over time.
“Researchers worldwide are focused on finding a treatment to COVID-19, and we are proud to provide advanced instrumentation to contribute to this effort,” said Jim Green, President and CEO of Harvard Bioscience. “This is a transformational technology that gives our customers the ability to know the delivered dose and the resulting lung function, all on an easy-to-use software platform.”
Integrating exposure and respiratory capabilities, this system delivers precise amounts of various aerosols to multiple subjects in a uniform, and reproducible manner, then measures pulmonary effects from the same platform. This technology and other new advancements in the Harvard Bioscience inhalation platform provide researchers with novel tools to study COVID-19 and advance development in both the discovery of new therapies and the pre-clinical regulatory phases, as solutions progress toward general clinical use.
Green added, “We are seeing immediate interest in our Buxco AIA system from CROs and pharmaceutical companies in China and around the world, and expect academic research demand to increase as researchers return to their labs. Notably, in spite of COVID-19’s impact on markets and world-wide supply chains, Harvard Bioscience is fortunate to continue to be in a position during this crisis to develop, manufacture and ship game-changing new products for research and drug development around the world.”